Furthermore, Pten activity is necessary for quiescence-based tumour suppression, as its deletion alleviates tumour suppression without affecting proliferation. These data demonstrate that stem cell quiescence is a form of tumour suppression in HFSCs, and that Pten plays a role in maintaining quiescence in the presence of tumorigenic stimuli.
the hair cycle controls tumorigenic sensitivity, a likely culprit could be stem cells and the regulation of their activation. Induction of anagen exacerbates progression of basal cell carcinoma, but is not required for initiation of phenotype 15 , demonstrating that quiescence in telogen is not a barrier to tumorigenesis for basal cell carcinoma 15, 16 .
It has been shown that HFSCs are sufficient to act as SCC cancer cells of origin using inducible, cell-type-specific, genetically defined mouse models 3, 4, 17 . However, these studies did not address a role for the hair cycle or stem cell activation during tumorigenesis. Here we demonstrate that HFSCs cannot initiate Kras G12D -or Kras G12D /p53 ffmediated tumorigenesis in quiescent HFSCs during telogen. Instead, tumorigenesis begins only when HFSCs are released from quiescence during a telogen-to-anagen transition.
RESULTS

Identification of stem cell quiescence-mediated tumour suppression
To determine which cells of the hair follicle are capable of initiating tumours that lead to cutaneous cancers, an inducible conditional strategy was employed to deliver tumorigenic stimuli to stem cells or transit-amplifying cells within the hair follicle 3, 4 . These experiments showed that HFSCs were cells of origin for SCC, whereas their transit-amplifying progeny were unable to generate tumours 3, 4 , but neither of these studies addressed whether stem cell activation plays a role in tumorigenesis.
In fact, there is a striking effect of the hair cycle on tumour initiation in this model. Treating K15-CrePR;Kras G12D animals with the progesterone receptor antagonist mifepristone initiates a recombination that removes a stop codon upstream of the constitutively active Kras G12D knock-in allele and induces expression in the stem cell compartment (the bulge). HFSC-driven tumorigenesis was morphologically evident as a hyperplastic bulge at the telogen-toanagen transition when Ras was activated either immediately before the transition in telogen 4 (Fig. 1a ) or during the transition ( Supplementary  Fig. 1A ). Hyperplasia of the follicle was also evident at two weeks following the telogen-to-anagen transition, when mifepristone was administered one week before the telogen-to-anagen transition (n = 3 mice; Fig. 1b ). In contrast, when Kras G12D was expressed during telogen for up to ten weeks without a telogen-to-anagen transition, no morphological evidence of bulge hyperplasia (n = 5 mice; Fig. 1c,d ) or induction of proliferation ( Supplementary Fig. 1B ) was evident, consistent with a lack of sensitivity to oncogenic Ras during HFSC quiescence. Taken together, these data suggest that Kras G12D -induced hyperplasias can arise immediately from HFSCs when active during the telogen-to-anagen transition, but are unable to form hyperplasias when quiescent, even up to ten weeks post induction.
To address whether the response of HFSCs to Kras G12D is specific to particular portions of the hair cycle, animals were treated with mifepristone during full anagen, at which time HFSCs have returned to a quiescent state. Two weeks following mifepristone administration, anagen hair follicles returned to telogen without exhibiting hyperplasia (n = 5 mice; Supplementary Fig. 1C ). HFSCs from both the control and Kras G12D -expressing anagen follicles did not exhibit proliferation during this period, as shown by lack of Ki67 staining ( Supplementary  Fig. 1D ). These data demonstrate that induction of Kras G12D expression during anagen is not sufficient to initiate hyperplasia. Together, these data suggested that tumour initiation from HFSCs requires a telogen-to-anagen transition.
To rule out the possibility that differential recombination efficiency could lead to the disparity in phenotype, we used a YFP lineage-tracing allele to quantify recombination at various time points in the protocol. During telogen, the recombination efficiency was 21% ± 4% after 4 days (n = 25 follicles), and the number of recombined cells did not significantly change on subsequent quantification at 14, 21 and 28 days (30% ± 6%, 28% ± 2% and 22% ± 3%, respectively). Similarly, mice pulsed with mifepristone for four days during anagen showed 21% recombination. This provides further evidence that a significant portion of bulge cells received the oncogenic stimulus in telogen, that these cells remained quiescent, and that recombination frequency was affected by the hair cycle.
Correlation of the hair cycle and SCC in human skin
To determine whether the hair cycle plays a role in initiation of human SCC, we assessed whether any correlation exists between the hair cycle and SCCs in human skin. Both SCC in situ and invasive SCC were quantified by morphological analysis across hundreds of follicles. The closest terminal hair to the tumour was examined for stage of hair cycle. Anagen was associated with 25/25 invasive SCC cases examined and in 38/41 SCC in situ cases examined ( Fig. 1g ). Despite the fact that ∼90% of hairs are typically in anagen in human skin, these numbers suggest a strong correlation between SCC and the active phase of the hair cycle.
Pten activity maintains stem cell quiescence in response to Ras activation
As the phosphatidylinositol-3-OH kinase (PI(3)K) pathway is activated downstream of Ras, we investigated whether negative regulators of the PI(3)K pathway were expressed during telogen, in the presence or absence of oncogene activation. Pten, a phosphatase that inhibits Akt pathway signaling, was identified as a likely candidate. Staining with a Pten antibody confirmed its presence in control telogen HFSCs ( Supplementary Fig. 1E ). To determine whether Pten prevents initiation of Kras G12D -induced tumorigenesis from telogen HFSCs, we bred animals harbouring a floxed version of the Pten allele to the K15-CrePR;Kras G12D line 18 and treated them with mifepristone during telogen (at 7-8 weeks of age). In contrast to K15-CrePR;Kras G12D bulges, which were similar to controls, K15-CrePR;Kras G12D ;Pten ff hair follicles demonstrated hyperplastic expansion during telogen ( Fig. 1e and Supplementary Fig. 1E ). Hyperplastic phenotypes were found in 26.9 ± 4.4% of all examined hair follicles in K15-CrePR;Kras G12D ;Pten ff skin (n = 3 mice, n = 1,361 follicles quantified). Furthermore, immunostaining for Pten showed that these hyperplastic structures seemed to have reduced or absent Pten expression ( Supplementary Fig. 1E ). To address whether loss of a single allele of Pten would suffice to promote proliferation in the context of Kras G12D , K15-CrePR;Kras G12D ;Pten wf mice were generated. Four weeks post mifepristone treatment, K15-CrePR;Kras G12D ;Pten wf skin did not exhibit bulge hyperplasias (n = 3 mice; Supplementary Fig. 1F ).
Pten does not control hair cycle initiation or proliferation
Two hypotheses could explain why K15-CrePR;Kras G12D ;Pten ff bulges produced hyperplasias during telogen. Pten deletion could induce a hair cycle de novo and thus allow for a response to Kras G12D activity or it could act to block Kras G12D -mediated downstream pathways during telogen. To distinguish between these two possibilities, K15-CrePR;Pten ff mice were generated to ablate Pten during telogen without inducing Kras G12D . Four weeks after induction of Pten deletion at 7-8 weeks of age, telogen K15-CrePR;Pten ff follicles neither spontaneously initiated a hair cycle ( Fig. 1f ) nor showed an increase in proliferation ( Supplementary Fig. 1G ). Although Pten seemed to be upregulated at the telogen-to-anagen transition in controls ( Supplementary Fig. 1H ), Pten staining was absent during a naturally occurring transition in K15-CrePR;Pten ff skin ( Supplementary Fig. 1I ), demonstrating effective Pten deletion. Taken together, these data suggest that Pten does not simply prevent entry into the hair cycle but instead acts to block a tumorigenic response to oncogenic Ras in quiescent HFSCs.
Telogen bulge hyperplasias do not arise from Lgr5 + or Lgr6 + cells
To refine the cells of origin for hyperplasias arising from telogen HFSCs, we employed alternative Cre drivers to express Kras G12D and thereby conditionally delete Pten. Whereas the K15-CrePR allele targets the entire bulge and hair germ, expression of the Lgr5-CreER allele is restricted to the hair germ and the lower region of the telogen bulge 19 . Lgr5-CreER;Kras G12D ;Pten ff animals were bred to determine whether the hair germ and lower bulge were sufficient to promote hyperplasia. Four weeks post tamoxifen treatment, telogen hair follicle bulges demonstrated no morphological change, indicating that the Lgr5-expressing population were not the cells of origin in this context (n = 3 mice; Fig. 2a ).
The Lgr6-CreER allele, which targets cells immediately above the bulge, as well as isolated cells of the interfollicular epidermis, was employed to further define the cells of hyperplasia origin 20 . Rare hyperplasias were found arising from Lgr6-CreER;Kras G12D ;Pten ff hair follicles, but these were morphologically distinct from those found in K15-CrePR;Kras G12D ;Pten ff telogen bulges (n = 3 mice). The phenotypes included hyperplasia of the sebaceous gland, infundibulum and interfollicular epidermis ( Fig. 2b) . In all cases, telogen bulges in Lgr6-CreER;Kras G12D ;Pten ff mice remained intact. Furthermore, the hyperplasias formed by the Lgr6 + cells outside the telogen bulge were morphologically distinct. These data indicate that the cells of origin for the hyperplasias found in K15-CrePR;Kras G12D ;Pten ff telogen HFSCs reside in the Lgr5 − upper bulge, below the Lgr6+ population.
Signalling pathways and transcription factors differentially regulated by loss of Pten and stem-cell quiescence-based tumour suppression
Pten acts as a negative regulator of Akt activation downstream of Ras. p-Akt, the activated form of Akt, is found only rarely in cells of control telogen bulges 21 (Fig. 3a ). K15-CrePR;Kras G12D telogen HFSCs did not show staining throughout this compartment ( Fig. 3a and Supplementary Fig. 2A ) and Pten-only deletion was not sufficient to activate Akt (Supplementary Fig. 2A ). Consistent with the mechanism of Pten activity, Pten deletion in the presence of Kras G12D expression resulted in high p-Akt staining in hyperplastic bulges ( Fig. 3a ). Non-phosphorylated Akt was found in control telogen HFSCs; thus, the change in activity was attributable to phosphorylation rather than a change in expression level ( Supplementary Fig. 1J ). These observations suggest that quiescent stem cells are refractory to the activation of Akt by Kras G12D through Pten and that Akt is a mediator of hyperplastic expansion. In addition to repression of Akt signalling, Pten has also been shown to repress the transcription factor activities of Creb and cJun [22] [23] [24] . Nuclear localization of p-Creb and p-cJun was found at high levels in hyperplastic bulges (Fig. 3b ,c), but not in normal skin (Fig. 3b,c and Supplementary Fig. 2B ,C). This is also interesting in light of data showing that Creb or Jun inhibition abrogates papilloma formation 25, 26 . To characterize the hyperplastic bulges in K15-CrePR;Kras G12D ;Pten ff skin, a number of hair follicle markers were assessed. Krt14, a marker of basal cells in stratified epithelia, was found throughout hyperplasias exhibiting basal epithelial morphology and in the outer layers of cyst structures ( Supplementary  Fig. 2D ). Krt6, a marker of hyperplastic epidermis, was also found throughout bulge hyperplasias ( Supplementary Fig. 2E ). Expression of Sox9, a HFSC marker, was found throughout the phenotypes that developed ( Supplementary Fig. 2F ), most likely owing to expansion of the bulge population.
Understanding mechanisms of tumour initiation through gene expression profiling
To identify the molecular basis for tumour suppression through stem cell quiescence, cells from induced K15-CrePR; LSL YFP, K15-CrePR;Kras G12D ; LSL YFP and K15-CreP;Kras G12D ;Pten ff ; LSL YFP skin were isolated by fluorescence-activated cell sorting (FACS) on the basis of YFP expression. Differential transcription profiles were generated by microarray comparing YFP + cells from K15-CrePR; LSL ;Pten ff telogen bulges were comparable to controls. (b) Expression of Kras G12D combined with Pten deletion to the Lgr6+ cells found above the bulge, and in some cells of the interfollicular epidermis, resulted in hyperplasias of the sebaceous gland, interfollicular epidermis and infundibular region.
Lgr6-CreER;Kras G12D
;Pten ff hyperplasias were morphologically distinct from the bulge hyperplasias found in K15-CrePR;Kras G12D ;Pten ff telogen bulges ( Fig. 1e ). SG Hy, sebaceous gland hyperplasia; IFE Hy, interfollicular epidermis hyperplasia; Inf Hy, infundibular region hyperplasia; Bl, bulge. All panels are shown at ×20. Scale bars, 100 µM.
the telogen-to-anagen transition were differentially regulated in K15-CrePR;Kras G12D ;Pten ff mice as compared with controls 27 (Fig. 4a ) including: Tgf-β (induced), Egf (induced), Bmp and Fgf (suppressed). In general, these data suggested that Pten deletion during telogen led to decreased expression of genes previously shown to promote the quiescent telogen state, whereas most of the genes thought to play a role in driving anagen were not induced. This indicates that Ras activation coupled with Pten deletion gives rise to HFSCs that are disinhibited by telogen and sensitive to tumour initiation.
As micro-RNAs (miRNAs) can regulate large sets of genes, miRNA profiling was employed to understand how some of the expression changes that underlie quiescence-based tumour suppression in HFSCs originated. YFP+ cells from K15-CrePR; LSL YFP telogen bulges and K15-CrePR;Kras G12D ;Pten ff ; LSL YFP telogen bulges were collected by FACS on the basis of YFP expression and profiled. Nuclear expression was found in the infundibulum and hair germ of control tissue, but no apparent staining was found in the control bulge.
(c) Nuclear p-cJun, indicating JNK pathway activation, was found at high levels in K15-CrePR;Kras G12D ;Pten ff bulge hyperplasias. Control bulges did not show any apparent staining, but p-cJun was found in the interfollicular epidermis and infundibulum. TnC, tenascin C. All panels are shown at ×20. Scale bars, 100 µM.
Thirty miRNAs were found to be induced at least 1.5-fold in K15-CrePR;Kras G12D ;Pten ff bulges ( Supplementary Fig. 3A) , and some of these changes were confirmed by PCR with reverse transcription (RT-PCR) on an independent sample (Fig. 4b) . The targets of seven upregulated miRNA families were found enriched amongst downregulated messenger RNAs detected by microarray profiling (Fig. 4b) suggesting that upregulation of these miRNAs played a functional role in the downregulation of a number of mRNAs ( Fig. 4b) . Interestingly, miR-21, the miRNA shown to have the highest number of differentially regulated targets, has been shown in numerous contexts to be induced by Tgf-β and Bmp activation [28] [29] [30] [31] [32] , and ablation of miR-21 abrogated squamous tumorigenesis in a DMBA/TPA protocol [33] [34] [35] [36] .
The signalling pathways suggested by the gene expression data as differentially activated were also assessed at the protein level. The Tgf-β pathway is activated during the telogen-to-anagen transition 37 , and was induced, as determined by phosphorylation of the effector protein Smad2, in K15-CrePR;Kras G12D ;Pten ff hyperplastic bulges ( Fig. 4d ) but absent in control, K15-CrePR;Kras G12D and K15-CrePR;Pten ff bulges ( Supplementary Fig. 4A ). Next, K15-CrePR;Kras G12D ;Pten ff hyperplasias stained strongly for active Egf receptor signalling (Fig. 4e ), but this was weak or absent in control, K15-CrePR;Kras G12D and K15-CrePR;Pten ff bulges ( Supplementary Fig. 4B; ref. 38 ). Wnt signalling, also thought to promote HFSC activation and the telogento-anagen transition 39 , was not induced in hyperplasia as assayed by nuclear localization of β-catenin and expression of known transcriptional targets of the Wnt pathway ( Supplementary Fig. 4E ). These data demonstrate that some activators of the hair cycle were present during K15-CrePR;Kras G12D ;Pten ff hyperplasia formation in telogen HFSCs but Wnt was not.
Fgf18 plays a critical role in telogen, as ablation of Fgf18 markedly shortens this quiescent phase 40 . Here, we found that staining with an Fgf18 antibody showed significantly reduced expression in K15-CrePR;Kras G12D ;Pten ff telogen bulges (Fig. 4f ), but not in K15-CrePR;Kras G12D and K15-CrePR;Pten ff telogen bulges ( Supplementary Fig. 4C ). Bmp signalling is also thought to maintain telogen and activity of this pathway can be measured by phosphorylation of Smad1/5/8 (ref. 41) . Consistent with this, we observed downregulation of Bmp ligands in K15-CrePR;Kras G12D ;Pten ff hyperplasias (Fig. 4a ). Unexpectedly, nuclear p-Smad1/5/8 stained strongly in proliferating K15-CrePR;Kras G12D ;Pten ff bulges and in hyperplastic structures (Fig. 4G ), but not in K15-CrePR;Kras G12D and K15-CrePR;Pten ff HFSCs ( Supplementary Fig. 4D ).
To summarize, K15-CrePR;Kras G12D ;Pten ff telogen bulges exhibited three features of activated HFSCs, notably high Tgf-β and Egf activity and low Fgf18 expression, but failed to exhibit other features, such as induction of Wnt or suppression of Bmp signalling. Thus, K15-CrePR;Kras G12D ;Pten ff bulges exist in an atypical state that allows for oncogenic Kras to promote hyperplasia in a normally refractive stem cell niche through only partially activated HFSCs.
Quiescent HFSCs are refractory to Kras G12D ; p53 ff cancer initiation
K15-CrePR;Kras G12D
;p53 ff mice did not initiate SCC when HFSCs were in telogen ( Fig. 5a,b) . Therefore, to determine whether Pten plays a role in stem cell quiescence-mediated prevention of carcinoma initiation we generated K15-CrePR;Kras G12D ;p53 ff ;Pten ff animals and examined them up to 4 weeks after mifepristone administration during telogen. In a striking departure from K15-CrePR;Kras G12D ;p53 ff animals, these animals produced macroscopically identifiable skin phenotypes one to ;Pten ff ; LSL YFP+ cells, microarray profiling was performed. The panels in a show ratios of gene expression for the indicated genotype relative to control HFSCs for selected genes known to influence HFSC activation and quiescence 8, 37 . (b) Left, histogram depicting ratio of percentage of target genes 2-fold or more downregulated divided by the percentage of target genes 2-fold or more upregulated among miRNA families upregulated 1.5-fold or more in YFP+K15-CrePR;Kras G12D ;Pten ff ; LSL YFP cells compared with YFP+ K15-CrePR; LSL YFP cells. Target genes of miR-21 were most commonly found amongst downregulated mRNAs, suggesting functional significance of miR-21 upregulation. Right, histogram of ratio of mRNA target genes upregulated by twofold versus those downregulated in YFP+K15-CrePR;Kras G12D ;Pten ff ; LSL YFP cells compared to YFP+ K15-CrePR; LSL YFP cells. This indicates that downregulation of just 3 miRNAs seemed to have a functional impact on mRNA levels. (c) Histogram depicting selected miRNA changes in YFP+ K15-CrePR;Kras G12D ;Pten ff ; LSL YFP cells compared with YFP+K15-CrePR; LSL YFP cells from an independent biological replicate by RT-PCR. (d) Smad2, an obligate transducer of Tgf-β signals, was phosphorylated in hyperplasias but not in telogen controls. (e) p-Egfr staining showed high levels of Egfr activity in K15-CrePR;Kras G12D ;Pten ff hyperplasias compared with controls. (f) Staining for Fgf18, known to maintain stem cell quiescence, was expressed in telogen control bulges but absent in K15-CrePR;Kras G12D ;Pten ff hyperplasias. (g) Bmp signalling, shown by phospho-Smad1/5/8, was high in K15-CrePR;Kras G12D ;Pten ff hyperplasias and low in telogen controls. a-d are shown at ×20. Scale bars, 100 µM. two weeks following induction with mifepristone (n = 4 mice). The skin malignancies that formed showed features of malignant trichoblastoma, malignant tricholemmoma, desmoplastic squamous cell carcinoma and spindle-cell squamous cell carcinoma ( Fig. 5c-f ). Consistent with these findings, tricholemmomas are characteristic of Cowden's disease, which occurs in human patients with Pten mutations 42 .
The signalling pathways previously implicated in the hyperplasias of K15-CrePR;Kras G12D ;Pten ff HFSCs where re-examined in the context of K15CrePR;Kras G12D ;p53 ff ;Pten ff malignancies. These tumours contained an epithelial component that retained E-cadherin expression, as well as a vimentin-expressing mesenchymal component that was composed of either cancer-associated fibroblasts or tumour cells that had undergone an epithelial to mesenchymal transition (Fig. 6a) , also suggested by some of the cells at the invasive front expressing both keratin 5 and vimentin ( Supplementary Fig. 4F) . The E-cad + tumour cells demonstrated high levels of p-Creb, p-Smad2, p-Smad1/5/8 and p-Egfr (Fig. 6c,e,f,g, third panel) , consistent with the notion that these pathways contribute to progression. In contrast to K15-CrePR;Kras G12D ;Pten ff hyperplasias, these malignancies showed low p-Akt and low p-cJun staining, suggesting that these pathways might not be critical for tumour progression (Fig. 6b,c, third panel) .
DISCUSSION
Using the hair follicle as a model system for tumorigenesis with a stem cell origin, we explored the potential influence of the cycling nature of stem cell activation and quiescence in tumour initiation. The data presented here demonstrate that quiescence can be used to suppress tumorigenesis in stem cells harbouring cancer-causing mutations. Adult stem cell activation occurs with varying frequencies in several organs, including almost continuously (intestine), cyclically (hair follicle), infrequently (mammary gland) or only in situations of necessary repair (prostate). Thus, the frequency of stem cell activation can have important implications when considering the latency of cancer initiation in humans. In some situations, adult stem cells that harbour the necessary mutations to generate a cancerous lesion could lay dormant for decades until activated, such as in cases of stem cell activation due to organ injury.
Induction of oncogenic Kras alone or oncogenic Kras combined with p53 knockout in HFSCs is sufficient to initiate tumorigenesis when the stem cells have been activated, but not when these cells are at rest in quiescence. Pten enables quiescence-based tumour suppression, because when deleted, quiescent HFSCs are able to initiate tumorigenesis. During the formation and progression of hyperplasias and malignancies arising from telogen stem cells a number of signalling cascades are active, namely the Tgf-β, Bmp and Egf pathways (Fig. 6 ). Furthermore, when Pten deletion is combined with Kras G12D expression and p53 deletion, normally quiescent HFSCs are capable of initiating SCC. In addition, a distinct set of miRNA families are differentially regulated during emergence of tumorigenesis in K15-CrePR;Kras G12D ;Pten ff skin, some of which seem to play a significant role in mRNA regulation during phenotype progression. Dissecting the intricate web of signalling, transcription factor activity and suppression of gene expression through miRNAs that control quiescence-based tumour suppression in HFSCs represents an important avenue of exploration.
These data also revealed an unusual situation in which simultaneous activation of both the Tgf-β and Bmp arms of the Tgf signalling cascades were found. This was surprising because these pathways are typically antagonistic to each other, particularly in the epidermis 37, 41 . In fact, downregulation of Bmp ligands was observed coincident with Tgf-β activation (Fig. 4A ), but this did not lead to decreased Smad1/5/8 activation (Fig. 4g ). Regardless, these results are evidence that loss of Pten combined with Ras activation promotes some aspects of anagen (Tgf-β signalling) but fails to remove some inhibitory aspects of telogen (Bmp signalling). This is consistent with the fact that a normal anagen follicle did not form in this setting.
The work presented here does not preclude a role for SCC initiation from the interfollicular epidermis (IFE). It is clear from work with human keratinocytes that cutaneous tumorigenesis can be initiated in the absence of hair follicles 43 . It remains controversial as to whether a hierarchy of developmental potential exists in the interfollicular epidermis or whether cells of the IFE cycle through periods of quiescence and activation. Owing to these limitations, it is difficult to determine whether stem cell quiescence also plays a role in suppression of tumorigenesis derived from the IFE.
The model presented here demonstrates that Pten is a key factor for maintaining HFSC quiescence in the face of oncogene activation, but does not necessarily suggest that Pten plays a role in SCC. Instead, Pten prevents tumour formation in quiescent HFSCs that normally occurs when Ras is activated. Although Pten mutations are not often found in human cutaneous SCC (refs 44-46), patients with loss of function mutations in Pten (Cowden's disease) exhibit increased tricholemmoma incidence and a higher risk of SCC (refs 46-48) . These data present a unique conceptual framework for cancer origination, with important implications for a range of tumours arising from various organs, particularly in those where turnover of stem cells is cyclical or that only activate during injury.
METHODS
Methods and any associated references are available in the online version of the paper. Pten ff ), the NCI MMHCC repository (LSL-Kras G12D and p53 ff ), and from the Clevers lab (Lgr6-CreER) and maintained under conditions set forth by IUCUC and ARC (UCLA; refs [49] [50] [51] . Except for those shown in Fig. 1a , all K15-CrePR; Kras G12D , K15-CrePR; Kras G12D ; p53 ff , K15-CrePR; Kras G12D ; Pten ff and K15-CrePR; Kras G12D ; Pten ff ; p53 ff animals were treated by intraperitoneal injections of mifepristone (10 mg ml −1 dissolved in sunflower seed oil, 2 mg per day) during telogen (roughly 7-8 weeks post natal, and monitored for hair regrowth following shaving), for 3-5 days. Phenotypes shown from treated animals were produced 3-4 weeks after mifepristone administration, without the beginning of the next anagen cycle. For Fig. 1b , animals were treated later in telogen (10 weeks post natal), allowing for anagen to proceed 1 week following. Skin was collected 3 weeks post initial mifepristone administration. For Supplementary Fig. 1A, animals were treated during a telogen-to-anagen transition for 3 days, and tissue was collected on the fourth day. For Supplementary Fig. 1C , animals were treated during anagen and skin was collected 2 weeks following the first treatment. Both male and female animals were used in this study in approximately equal numbers with no apparent difference in phenotype between genders. All phenotypes described are representative of a minimum of n = 3 animals as indicated in the description of each experiment. No statistical measure was used to determine the sample size beforehand, nor were statistics used to measure effects, as the results were essentially positive or negative as represented in the figures. The results described include data from all treated animals. The investigators were not blinded to allocation during the experimental data collection, nor were the experiments randomized. The results shown were representative images from at least three independently treated animals, and genotyping was performed both before and after animal treatment for confirmation.
Histopathological examination of human specimens. One hundred and eightyone excision specimens with a biopsy diagnosis of SCC in situ or SCC were examined from terminal hair-bearing skin (that is, scalp of men or women, or beards and arms of men) as previously described 52 . Specimens containing at least one terminal hair within the excision specimen were included whereas specimens containing only vellus hairs or vellus-like miniaturized hairs were excluded from the study. As vellus hairs presumably also cycle, there have not been any studies evaluating the stages of the hair cycle in vellus hairs or histological features of the vellus hair follicles at the different points in the hair cycle. For this reason, we limited our analysis to biopsy-proven SCCs from areas of skin that normally contain terminal hair follicles. In total, we examined 181 excision specimens from terminal hair-bearing areas (scalp and legs of men and women, and beard, cheeks, forearms and posterior necks of men). To be included, residual squamous cell carcinoma had to be present and at least one terminal hair had to be present on the excision specimen. However, most patients who had the diagnosis of SCC, even in normally hair-bearing areas, did not posses terminal hairs on the biopsy slide. This was probably due to age and the presence of androgenic alopecia as many specimens examined were obtained from elderly patients, and possessed miniaturized hair follicles, or 'vellus-like hairs' of androgenic alopecia, so these specimens could not be included. This was most true of scalp lesions. Following exclusion of specimens without residual squamous cell carcinoma and the presence of one terminal hair within the specimen, 66 samples met our criteria for analysis. Terminal hair follicles within, or the nearest adjacent terminal hair follicle to the tumour, if uninvolved, were examined for morphologic evidence of hair cycle. If vellus hairs or vellus-like miniaturized hairs were the nearest hair follicles to the tumour, those specimens were excluded as hair cycle characteristics for vellus or vellus-like hairs have not been established. All human data were approved by the Institutional Review Board at UCLA.
Immunostaining. Fresh frozen sections were cut at 8 µM for haematoxylin and eosin staining and immunofluorescence microscopy. Immunostaining was carried out on frozen sections as described previously. The following antibodies were used: rabbit p-Akt 1:200 (Ser473; D9E; Cell Signaling Technology, #4060), rabbit p-Creb (Ser133; 87G3; Cell Signaling Technology, #9198), rat tenascin C 1:1400 (Abcam, ab6346), rabbit p-cJun 1:200 (Ser73; D47G9; Cell Signaling, #3270), rabbit p-Smad2 1:75 (Ser465/467; 138D4; Cell Signaling Technology, #3108), rabbit p-Egfr (1:600; Y1068; Abcam, ab40815), rabbit Fgf18 1:100 (Sigma, HPA018795), rabbit p-Smad1/5/8 1:150 (Ser463/465; Millipore, ab3848), rabbit E-cadherin 1:100 (24E10; Cell Signaling Technology, #3195), chicken vimentin 1:1000 (Covance, PCK-594P), rabbit Ki67 1:400 (Abcam, ab15580), rabbit Pten 1:50 (D4.3; Cell Signaling Technology, #9188), rabbit Pten 1:100 (Millipore, 04-409), rabbit Akt 1:150 (C73H10) (Cell Signaling, #2938), rabbit keratin 14 1:800 (Covance, PRB-155P), rabbit keratin 6 1:800 (Covance, PRB-169P), rabbit Sox9 1:800 (Millipore, ab5535), beta-catenin 1:150 (H-102; Santa Cruz Biotechnology, sc-7199), rabbit keratin 5 1:1,000 (Covance, PRB-160P). Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue with citrate buffer antigen retrieval with the following antibodies: Ki67 (eBioscience), p-Akt, Akt, Pten (Cell Signaling), β-catenin (Santa Cruz) and Fgf18 (Sigma). SignalStain reagent (Cell Signaling) was used with Pten and Fgf18 antibodies to amplify signal. AEC (Vector Labs) was used for the colorimetric reaction.
Cell isolation and FACS. Whole dorsal and ventral mouse K15-CrePR; LSL YFP, K15-CrePR; Kras G12D ; LSL YFP and K15-CrePR; Kras G12D ; Pten ff ; LSL YFP were extracted, diced and digested with collagenase (20 mg ml −1 ) for 2 h at 37 • , and then an equal volume of 0.25% trypsin was added and digestion continued for a further hour at 37 • . Digested tissue was mechanically dispersed using a pipette and filtered with a 100 µM cell strainer, collected at 300g and washed twice with PBS. The cells were then filtered through a 40 µM cell strainer and FACS processed. YFP+ and YFP− cell populations were collected in RNA lysis buffer (Stratagene) and stored at −80 • .
Gene expression profiling.
Microarray analyses by GeneSpring software were performed as described previously 53 . Small RNA cloning, sequencing and annotation: construction of small RNA libraries was performed as described previously 54 . The small RNA libraries were sequenced using an Illumina HiSeq2000 sequencer and annotated as previously described 54 . All expression values and fold changes are derived from microarray analysis of at least two samples of YFP+ FACS-isolated cells. The gene expression data can be accessed at NIH GEO GSE51635.
Analysis of predicted target mRNAs regulated by micro-RNAs. The list of raw values from microarray data comparing YFP+ cells from K15-CrePR; Kras G12D
;p53 ff ;Pten ff ; LSL YFP with K15-CrePR; LSL YFP skin, as assessed by GeneSpring software, was modified by extracting low values (<100), duplicates and genes with multiple names. The list of differentially regulated miRNAs was then modified by extracting miRNA reads less than 100 and for differential regulation below 1.5-fold change up or down. TargetScan Mouse was used to compile predicted target genes from miRNAs up or downregulated more than 1.5-fold. The predicted target gene lists were then compared to the revised microarray using function vlookup in Microsoft Excel to determine target genes expression status. Common genes in miRNA and microarray lists were calculated for fold change between telogen controls to telogen experimental skin. The number of genes up, down, not present, or differentiatially regulation were quantified. The per cent downregulated over the per cent upregulated plus not changed was calculated and graphed. Finally, miRNAs with targets 1.5 or more downregulated over upregulated or not regulated were identified as non-random regulation by miRNAs amongst upregulated miRNAs, and miRNAs with targets 1.5 or more upregulated over downregulated or not regulated were identified as non-random regulation by miRNAs amongst downregulated miRNAs.
